NCT00007423View on ClinicalTrials.gov

Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2001

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

Trial Locations (2)

Unknown

UVRI - IAVI HIV Vaccine Program, Entebbe

Joint Clinical Research Center N09-002 CRS, Kampala

Sponsors
All Listed Sponsors
collaborator

Joint Clinical Research Center

OTHER

collaborator

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

collaborator

Joint UN Programme on HIV/AIDS (UNAIDS)

OTHER

collaborator

Fogarty International Center of the National Institute of Health

NIH

collaborator

Case Western Reserve University

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00007423 - Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda | Biotech Hunter | Biotech Hunter